DHARMESH BHATT (SEBI Regi. Research Analyst - (INH000009685) Total Revenue from operations for Q1FY27 stood at Rs 1,52,998.8 million, reflecting a YoY growth of 10.46% compared to Rs 1,38,514.0 million in Q1FY26 and a QoQ growth of 4.71% from Rs 1,46,117.9 million in Q4FY26. Total income for Q1FY27 was Rs 1,60,235.0 million, recording an increase of 11.93% YoY from Rs 1,43,158.6 million in Q1FY26 and an increase of 6.33% QoQ from Rs 1,50,702.9 million in Q4FY26. Profit before exceptional items and tax for Q1FY27 was Rs 43,029.0 million, a YoY growth of 7.82% from Rs 39,907.7 million in Q1FY26 and a QoQ growth of 21.16% from Rs 35,513.4 million in Q4FY26. Reported Net Profit (attributable to owners of the company) for Q1FY27 reached Rs 28,947.9 million, showing a growth of 27.04% YoY from Rs 22,786.3 million in Q1FY26 and a QoQ growth of 6.66% from Rs 27,140.3 million in Q4FY26. Adjusted net profit for Q1FY27 was reported at Rs 30,894 million, representing a YoY growth of 3.1% over Q1FY26. EBITDA for Q1FY27 stood at Rs 44,177 million, marking a growth of 2.7% YoY, with an EBITDA margin of 28.9%. Total Comprehensive Income (attributable to owners) for Q1FY27 was Rs 44,083.2 million, compared to Rs 23,959.2 million in Q1FY26 and Rs 42,135.3 million in Q4FY26. $SUNPHARMA

#StockInNews

781 likes·81 comments